Compare OLB & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OLB | PULM |
|---|---|---|
| Founded | 1993 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.4M | 6.2M |
| IPO Year | 2019 | 2013 |
| Metric | OLB | PULM |
|---|---|---|
| Price | $0.19 | $1.54 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 7.1M | 46.4K |
| Earning Date | 11-13-2026 | 10-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 71.48 | 46.18 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $8,676,907.00 | $7,910,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $67.27 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 5069.93 |
| 52 Week Low | $0.18 | $1.16 |
| 52 Week High | $1.80 | $5.24 |
| Indicator | OLB | PULM |
|---|---|---|
| Relative Strength Index (RSI) | 32.84 | 48.60 |
| Support Level | $0.18 | $1.44 |
| Resistance Level | $0.34 | $1.55 |
| Average True Range (ATR) | 0.02 | 0.10 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 10.59 | 37.87 |
The OLB Group Inc is a diversified FinTech company that focuses on a suite of products in the merchant services marketplace and seeks to provide integrated business solutions to merchants throughout the United States. The company seeks to provide merchants with a wide range-of-products and services through the various online platforms, including financial and transaction processing services. It also has products that provide support for crowdfunding and other capital-raising initiatives. It supplements the online platforms with certain hardware solutions that are integrated with the online platforms. The company has two business segments: Fintech Services, which generates key revenue, and the Bitcoin Mining business segment.
Pulmatrix Inc is a biopharmaceutical company focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).